Amy Mcbride Wendell Sells 5,000 Shares of AxoGen, Inc. (NASDAQ:AXGN) Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell sold 5,000 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the completion of the transaction, the director now directly owns 97,899 shares in the company, valued at approximately $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AxoGen Price Performance

NASDAQ:AXGN opened at $17.77 on Friday. AxoGen, Inc. has a one year low of $5.55 and a one year high of $21.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The firm has a market cap of $787.99 million, a price-to-earnings ratio of -55.53 and a beta of 1.00. The firm’s fifty day moving average is $17.87 and its two-hundred day moving average is $15.24.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AXGN. Canaccord Genuity Group upped their target price on AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $24.00 price target on shares of AxoGen in a report on Wednesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $20.75.

Institutional Investors Weigh In On AxoGen

Hedge funds have recently modified their holdings of the company. Quest Partners LLC boosted its stake in shares of AxoGen by 23,066.7% during the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 2,076 shares in the last quarter. R Squared Ltd purchased a new position in AxoGen in the 4th quarter valued at about $30,000. US Bancorp DE purchased a new position in AxoGen in the 4th quarter valued at about $30,000. State of Wyoming purchased a new position in AxoGen in the 4th quarter valued at about $31,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in AxoGen in the 4th quarter valued at about $93,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.